Verseon

The European Patent Office recently granted patent protection for our plasma (PK) inhibitors. PK is a validated target in diabetic (DR) and diabetic macular edema (DME), chronic diseases that lead to a form of vision loss associated with . Inhibiting PK also holds promise as a treatment for hereditary angioedema ( ), a potentially fatal condition characterized by severe swelling.

Verseon Receives European Patent for Innovative Compounds Covered compounds could provide revolutionary oral treatments for several chronic and fatal conditions

“Verseon...is fishing...in the largely uncharted ocean of chemical space, using molecular physics to accurately predict how new chemical structures will bind to particular proteins.”


BioSpace

BioSpace Says Verseon Is "Changing the Paradigm of Drug Discovery" "What sets Verseon apart is its use of molecular physics modeling to enable the atomic-level engineering of new molecules."

“Integrating AI and molecular modeling is likely to produce far more powerful breakthroughs in small molecule drug discovery than either approach could individually.”

Why AI Alone Cannot Find Tomorrow’s Medicines "AI is good at interpolating features within the bounds of a well-explored pool of training data but unable to make useful extrapolations far outside it."

"Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."

Impact Wealth Magazine

Verseon is Redefining the Delay, Prevention, and Treatment of Disease "Between its regulated pharmaceuticals and consumer healthspan products, Verseon ... will likely transform twenty-first century medicine and touch the lives of everyone on the planet."

“We’ve spent a decade and a half developing fundamental advancements in computational chemistry, molecular-physics modeling, and applications of AI to make systematic design of completely new drug molecules a reality.”



https://bit.ly/3OvqYgr

MarkTechPost Features Verseon’s CEO in AI in Healthcare Issue MarkTechPost Features Verseon’s CEO in AI in Healthcare Issue "… our ability to explore uncharted chemical space allows us to find drug candidates with uniquely desirable properties for the treatment of every disease we address."

Verseon is harnessing physics and AI to design unique drug treatments. https://bit.ly/3pQTZYe